. 2022 Sep 26;11(10):e220322. doi: 10.1530/EC-22-0322
This work is licensed under a Table 3.
Summary of the effect of supplementation with alpha-lipoic acid (each 500 mg/day) on levels of cardiometabolic risk factors in patients with type 2 diabetes.
| Outcome | Participants (studies) | Mean difference (95% CI) | MCID value | Clinically important? (≥MCID) | GRADE certainty |
|---|---|---|---|---|---|
| Primary outcomes | |||||
| HbA1c(%) | 782 (11) | −0.17 (−0.30, −0.05) | 0.5% | No | Moderate |
| BMI (kg/m2) | 563 (7) | −1.07 (−1.90, −0.25) | 1.5 kg/m2 | No | Low |
| Body weight (kg) | 349 (5) | −0.68 (−0.71, −0.64) | 4.4 kg | No | Moderate |
| LDL cholesterol (mg/dL) | 524 (9) | −5.05 (−12.93, 2.82) | 3.87 mg/dL | No | Very low |
| SBP (mmHg) | 388 (5) | −1.71 (−5.48, 2.07) | 2 mmHg | No | Very low |
| Secondary outcomes | |||||
| C-reactive protein (mg/dL) | 254 (3) | −0.03 (−0.04, −0.01) | 0.5 mg/dL | No | Low |
| DBP (mmHg) | 388 (5) | 1.03 (0.05, 2.02) | 2 mmHg | No | Low |
| FPG (mg/dL) | 620 (9) | −6.08 (−9.74, −2.42) | 29 mg/dL | No | Low |
| Triglyceride (mg/dL) | 669 (10) | −19.18 (−38.19, −0.17) | 8 mg/dL | No | Moderate |
| Total cholesterol (mg/dL) | 659 (10) | −3.57 (−24.36, 17.23) | 10 mg/dL | No | Very low |
| HDL cholesterol (mg/dL) | 609 (9) | 0.71 (−0.41, 1.83) | 3.87 mg/dL | No | Very low |
DBP, diastolic blood pressure; FPG, fasting plasma glucose; MCID, minimal clinically important difference; SBP, systolic blood pressure.